{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:07:52Z","timestamp":1780376872121,"version":"3.54.1"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Lipoprotein(a) [Lp(a)] and inflammation are critical drivers of residual risk. We aimed to evaluate the combined prognostic value of Lp(a) and a novel Inflammatory-Lipid Index [defined as hs\u2212CRP\u2009\u00d7\u2009(ApoB\/ApoA1)] in patients with acute coronary syndrome (ACS) and type 2 diabetes mellitus (T2DM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>\n                      A total of 1,910 patients with ACS and T2DM were analyzed over a median follow-up of 5.5 years. Multivariable Cox regression confirmed that both Lp(a) and the Inflammatory-Lipid Index were independent predictors of major adverse cardiovascular events (MACE). Restricted cubic splines revealed significant non-linear, positive correlations between these markers and MACE risk (both\n                      <jats:italic>P<\/jats:italic>\n                      for non\u2212linearity &amp;lt;0.001). Patients were stratified into four subgroups based on median values. Those in the dual-high group [high Lp(a) and high Inflammatory-Lipid Index] had the highest risk, with a MACE incidence of 57.7% and an 8-fold higher risk compared to the dual-low reference (HR: 8.01; 95% CI: 4.41\u201314.56;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001). Formal interaction analysis showed that the multiplicative interaction term was not statistically significant, whereas additive interaction analysis suggested an excess joint risk on the additive scale. Addition of both biomarkers to the conventional risk model improved predictive performance and reclassification (C-statistic: 0.741; NRI: 0.569; IDI: 0.053; all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001). In a sensitivity analysis using 3-point MACE, the overall pattern of association remained similar.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Concomitant elevation of Lp(a) and the Inflammatory-Lipid Index identifies a particularly high-risk phenotype among ACS patients with T2DM. This dual-biomarker approach significantly enhances cardiovascular risk stratification beyond traditional factors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1811591","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:29:19Z","timestamp":1780374559000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Combined prognostic value of lipoprotein(a) and an integrated inflammatory-lipid index in patients with acute coronary syndrome and type 2 diabetes mellitus"],"prefix":"10.3389","volume":"13","author":[{"given":"Tingting","family":"Li","sequence":"first","affiliation":[{"name":"Department of Cardiology, Tianjin Chest Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliang","family":"Cong","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tianjin Chest Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tianjin Chest Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ruo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tianjin Chest Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tianjin Chest Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12933-021-01311-9","article-title":"Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial","volume":"20","author":"Schwartz","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1161\/CIRCULATIONAHA.118.034645","article-title":"Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy","volume":"138","author":"Pradhan","year":"2018","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"841545","DOI":"10.3389\/fcvm.2022.841545","article-title":"Modified lipoproteins induce arterial wall inflammation during atherogenesis","volume":"9","author":"Lorey","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B4","first-page":"45","article-title":"Type 2 diabetes mellitus, oxidative stress and inflammation: examining the links","volume":"11","author":"Oguntibeju","year":"2019","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11789-017-0084-1","article-title":"Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies","volume":"12","author":"Ors\u00f3","year":"2017","journal-title":"Clin Res Cardiol Suppl"},{"key":"B6","doi-asserted-by":"publisher","first-page":"100350","DOI":"10.1016\/j.ahjo.2025.100581","article-title":"Lipoprotein (a) in primary cardiovascular disease prevention is actionable today","volume":"37","author":"Parcha","year":"2024","journal-title":"Am Heart J Plus"},{"key":"B7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.7860\/JCDR\/2014\/7588.4000","article-title":"Apo B\/Apo A-I ratio is statistically a better predictor of cardiovascular disease (CVD) than conventional lipid profile: a study from Kathmandu Valley, Nepal","volume":"8","author":"Tamang","year":"2014","journal-title":"J Clin Diagn Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12944-024-02055-7","article-title":"The predictive value of the hs-CRP\/HDL-C ratio, an inflammation-lipid composite marker, for cardiovascular disease in middle-aged and elderly people: evidence from a large national cohort study","volume":"23","author":"Gao","year":"2024","journal-title":"Lipids Health Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1392859","DOI":"10.3389\/fendo.2024.1392859","article-title":"Synergistic effect of lipoprotein(a) and high-sensitivity C-reactive protein on the risk of all-cause and cardiovascular death in patients with acute myocardial infarction: a large prospective cohort study","volume":"15","author":"Wang","year":"2024","journal-title":"Front Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jacc.2023.10.039","article-title":"Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein B-based genetic analysis","volume":"83","author":"Bj\u00f6rnson","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","article-title":"Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial","volume":"41","author":"Szarek","year":"2020","journal-title":"Eur Heart J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3389\/fcvm.2018.00062","article-title":"Antiinflammatory therapy in clinical care: the CANTOS trial and beyond","volume":"5","author":"Aday","year":"2018","journal-title":"Front Cardiovasc Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000001780","article-title":"Colchicine for major adverse cardiovascular events: an updated ChatGPT-assisted systematic review and meta-analysis","author":"Teperikidis","year":"2025","journal-title":"J Cardiovasc Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3390\/metabo11100690","article-title":"Apolipoprotein B and cardiovascular disease: biomarker and potential therapeutic target","volume":"11","author":"Behbodikhah","year":"2021","journal-title":"Metabolites"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1161\/ATVBAHA.108.179705","article-title":"Inflammation in atherosclerosis","volume":"32","author":"Libby","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"13043","DOI":"10.1073\/pnas.192399699","article-title":"C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids","volume":"99","author":"Chang","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1194\/jlr.M700535-JLR200","article-title":"Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats","volume":"49","author":"Singh","year":"2008","journal-title":"J Lipid Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.cyto.2011.09.029","article-title":"Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: a cross-sectional study","volume":"57","author":"Mirza","year":"2012","journal-title":"Cytokine"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.jacc.2021.07.016","article-title":"High-sensitivity C-reactive protein modifies the cardiovascular risk of lipoprotein(a): multi-ethnic study of atherosclerosis","volume":"78","author":"Zhang","year":"2021","journal-title":"J Am Coll Cardiol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1811591\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:29:20Z","timestamp":1780374560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1811591\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":19,"alternative-id":["10.3389\/fcvm.2026.1811591"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1811591","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"article-number":"1811591"}}